Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy.

Cytomegalovirus (CMV) strains resistant to ganciclovir have been associated with specific mutations in the UL97 and UL54 genes. The UL97 gene of a CMV strain isolated from a renal transplant recipient before and after 438 days of ganciclovir treatment was amplified by polymerase chain reaction and sequenced. A novel mutation resulting in deletion of codons 595 to 603 was identified in the viral DNA from specimens obtained after, but not before, prolonged ganciclovir therapy. Clinical and virological resolution of CMV disease occurred after switching to foscarnet therapy. Although many ganciclovir resistance mutations have been mapped to the UL97 codon range 591-607, this one is unusual in that it involves deletion of half these codons. Because UL97 seems to be necessary for effective CMV replication, this deletion suggests that much of codons 591-607 can be removed without destroying the biological function of UL97, and that this codon range can be altered in various ways to affect ganciclovir susceptibility. Rapid, flexible genotypic assays directed at this part of UL97 may facilitate the early recognition of ganciclovir resistance.

[1]  F. Baldanti,et al.  The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients , 1998, Antimicrobial Agents and Chemotherapy.

[2]  S. Chou,et al.  Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[3]  J. Rabkin,et al.  Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. , 1997, Transplantation.

[4]  D. Michel,et al.  The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase , 1996, Journal of virology.

[5]  D. Snydman,et al.  Cytomegalovirus prophylaxis in solid organ transplant recipients. , 1996, Transplantation.

[6]  G. Roberts,et al.  Molecular probes for diagnosis of fungal infections , 1995, Journal of clinical microbiology.

[7]  S. Chou,et al.  Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. , 1995, The Journal of infectious diseases.

[8]  S. Chou,et al.  Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. , 1995, The Journal of infectious diseases.

[9]  C. Payá,et al.  Comparison of three methods for extraction of viral nucleic acids from blood cultures , 1995, Journal of clinical microbiology.

[10]  W. Owen,et al.  Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. , 1991, The Journal of infectious diseases.

[11]  M. Chee,et al.  Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. , 1989, The Journal of general virology.

[12]  H. Balfour,et al.  Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. , 1989, The New England journal of medicine.

[13]  H. Balfour,et al.  Cytomegalovirus Disease in Renal Allograft Recipients: A Prospective Study of the Clinical Features, Risk Factors and Impact on Renal Transplantation , 1980, Medicine.